PharmaCyte Biotech Inc

NASDAQ: PMCB    
Share price (5/3/24): $2.16    
Market cap (5/3/24): $18.3 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.4
from 8-K 12 pages Collaboration Agreement
12/34/56
EX-10.3
from 8-K 16 pages Registration Rights Agreement
12/34/56
EX-10.2
from 8-K 31 pages Form of Senior Unsecured Convertible Note
12/34/56
EX-10.1
from 8-K 36 pages Securities Purchase Agreement
12/34/56
EX-10.3
from 8-K 12 pages A. Appointment of Katalyst
12/34/56
EX-10.2
from 8-K 22 pages Registration Rights Agreement
12/34/56
EX-10.1
from 8-K 40 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 3 pages Release Agreement
12/34/56
EX-10.1
from 8-K 10 pages Separation, Consulting and Release Agreement
12/34/56
EX-10.2
from DEFA14A 4 pages Via Email Only August 12, 2022 Re: Director Offer Letter Dear , This Director Offer Letter Constitutes an Agreement (“Agreement”) Between You and PharmaCyte Biotech, Inc. (“Company”) and Contains All of the Terms and Conditions Relating to Your Service to the Company as a Member of Our Board of Directors (“Board”)
12/34/56
EX-10.2
from 8-K 4 pages Via Email Only August 12, 2022 Re: Director Offer Letter Dear , This Director Offer Letter Constitutes an Agreement (“Agreement”) Between You and PharmaCyte Biotech, Inc. (“Company”) and Contains All of the Terms and Conditions Relating to Your Service to the Company as a Member of Our Board of Directors (“Board”)
12/34/56
EX-10.1
from DEFA14A 12 pages Cooperation Agreement
12/34/56
EX-10.1
from 8-K 12 pages Cooperation Agreement
12/34/56
EX-10.42
from 10-K 11 pages 2021 Plan PharmaCyte Biotech, Inc. 2021 Equity Incentive Plan
12/34/56
EX-10.41
from 10-K 4 pages Amended and Restated Executive Compensation Agreement
12/34/56
EX-10.40
from 10-K 14 pages Amended and Restated Executive Compensation Agreement
12/34/56
EX-10.1
from 8-K 33 pages Securities Purchase Agreement
12/34/56
EX-10.1
from S-3 9 pages Indemnification Agreement
12/34/56
EX-10.1
from 8-K 2 pages Amendment No. 3 to Executive Compensation Agreement
12/34/56
EX-10.2
from 10-Q 1 page Amendment No. 1 to Right of First Refusal Agreement
12/34/56